{
    "info": {
        "nct_id": "NCT03647163",
        "official_title": "Phase 1-2 Trial of Systemically Administered VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Selected Solid Tumors",
        "inclusion_criteria": "* Histologically confirmed diagnosis of:\n\n  * Arm 1: dose level 1 and below: Advanced and/or metastatic solid tumors for which no existing options are felt to provide clinical benefit\n  * Arm 2: dose level 2: Advanced and/or metastatic NSCLC OR NEC in which radiological progression has been demonstrated during therapy with a PD-1/PD-L1 immune checkpoint inhibitor, and for which no existing options are felt to provide clinical benefit.\n  * Arm 3: Advanced and/or metastatic NEC in which radiological progression has been demonstrated during therapy with a PD-1/PD-L1 immune checkpoint inhibitor, and for which no existing options are felt to provide clinical benefit.\n  * Arm 4: Advanced and/or metastatic NSCLC in which radiological progression has been demonstrated during therapy with a PD-1/PD-L1 immune checkpoint inhibitor, and for which no existing options are felt to provide clinical benefit.\n  * Arm 5: NEC: poorly differentiated NEC (large or small cell, or not further specified) with progressive disease following at least one prior line of systemic therapy.\n  * Arm 6: RCC: histologically confirmed diagnosis of advanced or metastatic RCC, including all IMDC risk categories (favorable, intermediate, and poor risk).\n* Measurable disease based on RECIST 1.1. The first 3 patients in the safety run-in phase do not need measurable disease. Part C: advanced NEC (neuroendocrine carcinoma based on histopathology according to WHO criteria. Patients with small cell carcinoma, large cell neuroendocrine carcinoma, and neuroendocrine carcinoma not otherwise specified, of any primary organ are eligible in which radiological progression has been demonstrated during therapy with a PD-(L)1 immune checkpoint inhibitor, and for which no existing options are felt to provide clinical benefit.\n* Performance status of 0 or 1 on the ECOG Performance Scale.\n* Life expectancy of >3 months if not on active anti-cancer therapy\n* Willingness to provide biological samples required for the duration of the study including a fresh tumor biopsy sample.\n* Adequate organ function using predefined laboratory values obtained ≤14 days prior to registration.\n* Negative pregnancy test for female patients of childbearing potential\n* Absence of active CNS involvement. NOTE: Pre-enrollment imaging of asymptomatic patients not mandatory\n* Ability to provide written informed consent.\n* Willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Availability of and patient acceptance of curative therapy.\n\n  a. For NSCLC cohort: i. Known EGFR mutations which are sensitive to available targeted inhibitor therapy (including, but not limited to, deletions in exon 19 and exon 21 [L858R] substitution mutations). All patients with non-squamous histology must have been tested for EGFR mutation status; use of an FDA-approved test is strongly encouraged. ii. Non-squamous histology and unknown or indeterminate EGFR status. b. Part D NSCLC cohort: Known ALK translocations which are sensitive to available targeted inhibitor therapy. If tested, use of an FDA-approved test is strongly encouraged. Patients with unknown or indeterminate ALK status may be enrolled.\n* Recent or ongoing serious infection, including:\n\n  1. Any active Grade 3 or higher (per the NCI CTCAE, version 4.03) viral, bacterial, or fungal infection within 2 weeks of registration.\n  2. Known seropositivity for or active infection by the human immunodeficiency virus (HIV).\n  3. Acute hepatitis B or acute hepatitis C. Patients with chronic hepatitis B or hepatitis C may be enrolled provided their liver function is adequate as per section 3.17\n  4. Known history of active TB (Bacillus tuberculosis).\n* Any serious health condition, which, in the opinion of the investigator, would place the patient at undue risk from the study, including uncontrolled hypertension and/or diabetes, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease requiring hospitalization within 3 months) or neurological disorder (e.g., seizure disorder active within 3 months)\n* Prior therapy within the following timeframe before the planned start of study treatment as follows:\n\n  * Chemotherapy, small molecule inhibitors, radiation, interventional radiology procedure, and/or other investigational agent: ≤3 weeks or 5 half-lives, whichever is shorter\n  * Other monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or experimental therapies: ≤4 weeks (≤3 weeks with documented disease progression)\n  * Prior palliative radiotherapy to non-CNS lesions must have been completed at least 2 weeks prior to randomization. Subjects with symptomatic tumor lesions at baseline that may require palliative radiotherapy within 4 weeks of randomization are strongly encouraged to receive palliative radiotherapy prior to randomization.\n  * NSCLC patients only: prior chemotherapy or immunotherapy or a combination of chemotherapy and immunotherapy for stage IV NSCLC.\n  * RCC patients:\n\n    i. Previously received a CTLA-4 inhibitor in the first-line setting. ii. Relapsed/progressed during adjuvant immunotherapy with a PD-(L)1 inhibitor or relapse within 12 months after completion of adjuvant immunotherapy\n* New York Heart Association classification III or IV, known symptomatic coronary artery disease, or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias (atrial fibrillation or SVT) (Appendix II).\n* Any known or suspected active organ-threatening autoimmune disease, such as inflammatory bowel disease, autoimmune hepatitis, lupus, or pneumonitis, with the exception of hypothyroidism and type 1 diabetes that are controlled with treatment.\n* Immunodeficiency or immunosuppression, including systemic corticosteroids at >10mg/day prednisone or equivalent within 1 week prior to planned start of study treatment\n* History of severe immune-mediated adverse reaction to immune checkpoint inhibitors.\n* Toxicities from previous therapies that have not resolved to a grade 1 or less.\n* History of non-infectious pneumonitis that required steroids, or current pneumonitis, or carcinomatous meningitis, or interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.\n* High volume disease, as assessed clinically via parameters such as radiologic impression and tumor markers or LDH.\n* Portal vein thrombosis involving more than intrahepatic portal vein branches: thrombosis of the right or left portal vein branch or the bifurcation, partial or complete obstruction of the portal vein trunk.\n* Known concurrent malignancy that is progressing or requires active treatment. EXCEPTIONS: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in-situ cervical cancer that has been treated with curative intent, prostate cancer confined to the prostate gland with Gleason score <6 or PSA <1, as well as any stage I cancer treated with curative intent or any prior cancer with a disease-free interval of ≥3 years.\n* Other concurrent anti-cancer therapy (chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (used for a non-FDA approved indication and in the context of a research investigation)).\n* Neuroendocrine neoplasms described as \"well-differentiated\" or \"moderately differentiated\" on pathologic review, or reported as \"carcinoid\", i.e., not true poorly differentiated neuroendocrine carcinoma [Nagtegaal 2020].\n* Has received a live vaccine within 30 days of planned start of study treatment. Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are NOT allowed.\n* Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:\n\n  * Pregnant women or women of reproductive ability who are unwilling to use highly effective contraception\n  * Nursing women\n  * Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatment.\n* Prisoners or subjects who are involuntarily incarcerated.\n* Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Absence of active CNS involvement. NOTE: Pre-enrollment imaging of asymptomatic patients not mandatory",
            "criterions": [
                {
                    "exact_snippets": "Absence of active CNS involvement",
                    "criterion": "active CNS involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to provide written informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Ability to provide written informed consent.",
                    "criterion": "ability to provide written informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Arm 5: NEC: poorly differentiated NEC (large or small cell, or not further specified) with progressive disease following at least one prior line of systemic therapy.",
            "criterions": [
                {
                    "exact_snippets": "poorly differentiated NEC (large or small cell, or not further specified)",
                    "criterion": "neuroendocrine carcinoma (NEC) differentiation",
                    "requirements": [
                        {
                            "requirement_type": "differentiation",
                            "expected_value": "poorly differentiated"
                        }
                    ]
                },
                {
                    "exact_snippets": "large or small cell, or not further specified",
                    "criterion": "neuroendocrine carcinoma (NEC) cell type",
                    "requirements": [
                        {
                            "requirement_type": "cell type",
                            "expected_value": [
                                "large cell",
                                "small cell",
                                "not further specified"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "progressive disease",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "following at least one prior line of systemic therapy",
                    "criterion": "prior systemic therapy lines",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willingness to provide biological samples required for the duration of the study including a fresh tumor biopsy sample.",
            "criterions": [
                {
                    "exact_snippets": "Willingness to provide biological samples required for the duration of the study",
                    "criterion": "biological sample provision",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "for the duration of the study"
                        }
                    ]
                },
                {
                    "exact_snippets": "including a fresh tumor biopsy sample",
                    "criterion": "fresh tumor biopsy sample provision",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Arm 1: dose level 1 and below: Advanced and/or metastatic solid tumors for which no existing options are felt to provide clinical benefit",
            "criterions": [
                {
                    "exact_snippets": "Advanced and/or metastatic solid tumors",
                    "criterion": "solid tumors",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "for which no existing options are felt to provide clinical benefit",
                    "criterion": "existing treatment options",
                    "requirements": [
                        {
                            "requirement_type": "clinical benefit from existing options",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function using predefined laboratory values obtained ≤14 days prior to registration.",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function using predefined laboratory values obtained ≤14 days prior to registration.",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Arm 3: Advanced and/or metastatic NEC in which radiological progression has been demonstrated during therapy with a PD-1/PD-L1 immune checkpoint inhibitor, and for which no existing options are felt to provide clinical benefit.",
            "criterions": [
                {
                    "exact_snippets": "Advanced and/or metastatic NEC",
                    "criterion": "NEC (neuroendocrine carcinoma) disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "radiological progression has been demonstrated during therapy with a PD-1/PD-L1 immune checkpoint inhibitor",
                    "criterion": "radiological progression during PD-1/PD-L1 inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy_type",
                            "expected_value": "PD-1/PD-L1 immune checkpoint inhibitor"
                        }
                    ]
                },
                {
                    "exact_snippets": "no existing options are felt to provide clinical benefit",
                    "criterion": "availability of existing clinical benefit options",
                    "requirements": [
                        {
                            "requirement_type": "clinical benefit from existing options",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of >3 months if not on active anti-cancer therapy",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of >3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if not on active anti-cancer therapy",
                    "criterion": "active anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "current treatment status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed diagnosis of:",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed diagnosis of:",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histological"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Arm 4: Advanced and/or metastatic NSCLC in which radiological progression has been demonstrated during therapy with a PD-1/PD-L1 immune checkpoint inhibitor, and for which no existing options are felt to provide clinical benefit.",
            "criterions": [
                {
                    "exact_snippets": "Advanced and/or metastatic NSCLC",
                    "criterion": "NSCLC stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "radiological progression has been demonstrated during therapy with a PD-1/PD-L1 immune checkpoint inhibitor",
                    "criterion": "radiological progression during PD-1/PD-L1 inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy type",
                            "expected_value": "PD-1/PD-L1 immune checkpoint inhibitor"
                        }
                    ]
                },
                {
                    "exact_snippets": "no existing options are felt to provide clinical benefit",
                    "criterion": "standard treatment options",
                    "requirements": [
                        {
                            "requirement_type": "clinical benefit from existing options",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease based on RECIST 1.1. The first 3 patients in the safety run-in phase do not need measurable disease. Part C: advanced NEC (neuroendocrine carcinoma based on histopathology according to WHO criteria. Patients with small cell carcinoma, large cell neuroendocrine carcinoma, and neuroendocrine carcinoma not otherwise specified, of any primary organ are eligible in which radiological progression has been demonstrated during therapy with a PD-(L)1 immune checkpoint inhibitor, and for which no existing options are felt to provide clinical benefit.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease based on RECIST 1.1.",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "The first 3 patients in the safety run-in phase do not need measurable disease.",
                    "criterion": "measurable disease (safety run-in phase)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "phase",
                            "expected_value": "first 3 patients in safety run-in"
                        }
                    ]
                },
                {
                    "exact_snippets": "Part C: advanced NEC (neuroendocrine carcinoma based on histopathology according to WHO criteria.",
                    "criterion": "advanced neuroendocrine carcinoma (NEC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "neuroendocrine carcinoma"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        },
                        {
                            "requirement_type": "diagnostic_method",
                            "expected_value": "histopathology according to WHO criteria"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with small cell carcinoma, large cell neuroendocrine carcinoma, and neuroendocrine carcinoma not otherwise specified, of any primary organ are eligible",
                    "criterion": "carcinoma subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "small cell carcinoma",
                                "large cell neuroendocrine carcinoma",
                                "neuroendocrine carcinoma not otherwise specified"
                            ]
                        },
                        {
                            "requirement_type": "primary_organ",
                            "expected_value": "any"
                        }
                    ]
                },
                {
                    "exact_snippets": "radiological progression has been demonstrated during therapy with a PD-(L)1 immune checkpoint inhibitor",
                    "criterion": "radiological progression during PD-(L)1 inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": "radiological progression"
                        },
                        {
                            "requirement_type": "therapy",
                            "expected_value": "PD-(L)1 immune checkpoint inhibitor"
                        }
                    ]
                },
                {
                    "exact_snippets": "for which no existing options are felt to provide clinical benefit.",
                    "criterion": "lack of existing clinical benefit options",
                    "requirements": [
                        {
                            "requirement_type": "clinical benefit from existing options",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Negative pregnancy test for female patients of childbearing potential",
            "criterions": [
                {
                    "exact_snippets": "Negative pregnancy test",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "female patients of childbearing potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Arm 6: RCC: histologically confirmed diagnosis of advanced or metastatic RCC, including all IMDC risk categories (favorable, intermediate, and poor risk).",
            "criterions": [
                {
                    "exact_snippets": "histologically confirmed diagnosis of advanced or metastatic RCC",
                    "criterion": "renal cell carcinoma (RCC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "histologically confirmed"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "including all IMDC risk categories (favorable, intermediate, and poor risk)",
                    "criterion": "IMDC risk category",
                    "requirements": [
                        {
                            "requirement_type": "category",
                            "expected_value": [
                                "favorable",
                                "intermediate",
                                "poor"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Performance status of 0 or 1 on the ECOG Performance Scale.",
            "criterions": [
                {
                    "exact_snippets": "Performance status of 0 or 1 on the ECOG Performance Scale",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Arm 2: dose level 2: Advanced and/or metastatic NSCLC OR NEC in which radiological progression has been demonstrated during therapy with a PD-1/PD-L1 immune checkpoint inhibitor, and for which no existing options are felt to provide clinical benefit.",
            "criterions": [
                {
                    "exact_snippets": "Advanced and/or metastatic NSCLC OR NEC",
                    "criterion": "cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "advanced NSCLC",
                                "metastatic NSCLC",
                                "advanced NEC",
                                "metastatic NEC"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "radiological progression has been demonstrated during therapy with a PD-1/PD-L1 immune checkpoint inhibitor",
                    "criterion": "radiological progression during PD-1/PD-L1 inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy type",
                            "expected_value": "PD-1/PD-L1 immune checkpoint inhibitor"
                        }
                    ]
                },
                {
                    "exact_snippets": "no existing options are felt to provide clinical benefit",
                    "criterion": "availability of alternative clinical benefit options",
                    "requirements": [
                        {
                            "requirement_type": "clinical benefit from existing options",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.",
            "criterions": [
                {
                    "exact_snippets": "Willing and able to comply with scheduled visits",
                    "criterion": "compliance with scheduled visits",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Willing and able to comply with ... treatment schedule",
                    "criterion": "compliance with treatment schedule",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Willing and able to comply with ... laboratory testing",
                    "criterion": "compliance with laboratory testing",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Prior palliative radiotherapy to non-CNS lesions must have been completed at least 2 weeks prior to randomization. Subjects with symptomatic tumor lesions at baseline that may require palliative radiotherapy within 4 weeks of randomization are strongly encouraged to receive palliative radiotherapy prior to randomization.",
            "criterions": [
                {
                    "exact_snippets": "Prior palliative radiotherapy to non-CNS lesions must have been completed at least 2 weeks prior to randomization",
                    "criterion": "prior palliative radiotherapy to non-CNS lesions",
                    "requirements": [
                        {
                            "requirement_type": "completion time before randomization",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with symptomatic tumor lesions at baseline that may require palliative radiotherapy within 4 weeks of randomization are strongly encouraged to receive palliative radiotherapy prior to randomization",
                    "criterion": "symptomatic tumor lesions at baseline that may require palliative radiotherapy within 4 weeks of randomization",
                    "requirements": [
                        {
                            "requirement_type": "recommendation to receive palliative radiotherapy prior to randomization",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior therapy within the following timeframe before the planned start of study treatment as follows:",
            "criterions": [
                {
                    "exact_snippets": "Prior therapy within the following timeframe before the planned start of study treatment",
                    "criterion": "prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to study treatment",
                            "expected_value": "within the following timeframe before the planned start"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:",
            "criterions": [
                {
                    "exact_snippets": "this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown",
                    "criterion": "exposure to investigational agent with unknown genotoxic, mutagenic, and teratogenic effects",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agent effect knowledge",
                            "expected_value": "unknown"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received a live vaccine within 30 days of planned start of study treatment. Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are NOT allowed.",
            "criterions": [
                {
                    "exact_snippets": "Has received a live vaccine within 30 days of planned start of study treatment",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "vaccine type",
                            "expected_value": "live"
                        }
                    ]
                },
                {
                    "exact_snippets": "Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed",
                    "criterion": "seasonal influenza vaccine for injection",
                    "requirements": [
                        {
                            "requirement_type": "vaccine type",
                            "expected_value": "inactivated"
                        },
                        {
                            "requirement_type": "route of administration",
                            "expected_value": "injection"
                        },
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are NOT allowed",
                    "criterion": "intranasal influenza vaccine",
                    "requirements": [
                        {
                            "requirement_type": "vaccine type",
                            "expected_value": "live attenuated"
                        },
                        {
                            "requirement_type": "route of administration",
                            "expected_value": "intranasal"
                        },
                        {
                            "requirement_type": "allowance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* RCC patients:",
            "criterions": [
                {
                    "exact_snippets": "RCC patients",
                    "criterion": "renal cell carcinoma (RCC) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Toxicities from previous therapies that have not resolved to a grade 1 or less.",
            "criterions": [
                {
                    "exact_snippets": "Toxicities from previous therapies that have not resolved to a grade 1 or less",
                    "criterion": "toxicities from previous therapies",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recent or ongoing serious infection, including:",
            "criterions": [
                {
                    "exact_snippets": "Recent or ongoing serious infection",
                    "criterion": "serious infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recency_or_ongoing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* New York Heart Association classification III or IV, known symptomatic coronary artery disease, or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias (atrial fibrillation or SVT) (Appendix II).",
            "criterions": [
                {
                    "exact_snippets": "New York Heart Association classification III or IV",
                    "criterion": "New York Heart Association classification",
                    "requirements": [
                        {
                            "requirement_type": "classification",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "known symptomatic coronary artery disease",
                    "criterion": "symptomatic coronary artery disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "symptoms of coronary artery disease on systems review",
                    "criterion": "symptoms of coronary artery disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known cardiac arrhythmias (atrial fibrillation or SVT)",
                    "criterion": "cardiac arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "atrial fibrillation",
                                "SVT"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any known or suspected active organ-threatening autoimmune disease, such as inflammatory bowel disease, autoimmune hepatitis, lupus, or pneumonitis, with the exception of hypothyroidism and type 1 diabetes that are controlled with treatment.",
            "criterions": [
                {
                    "exact_snippets": "Any known or suspected active organ-threatening autoimmune disease, such as inflammatory bowel disease, autoimmune hepatitis, lupus, or pneumonitis, with the exception of hypothyroidism and type 1 diabetes that are controlled with treatment.",
                    "criterion": "organ-threatening autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "organ-threatening"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "hypothyroidism that is controlled with treatment",
                                "type 1 diabetes that are controlled with treatment"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chemotherapy, small molecule inhibitors, radiation, interventional radiology procedure, and/or other investigational agent: ≤3 weeks or 5 half-lives, whichever is shorter",
            "criterions": [
                {
                    "exact_snippets": "Chemotherapy, small molecule inhibitors, radiation, interventional radiology procedure, and/or other investigational agent: ≤3 weeks or 5 half-lives, whichever is shorter",
                    "criterion": "prior therapy washout period",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* High volume disease, as assessed clinically via parameters such as radiologic impression and tumor markers or LDH.",
            "criterions": [
                {
                    "exact_snippets": "High volume disease, as assessed clinically via parameters such as radiologic impression",
                    "criterion": "disease volume",
                    "requirements": [
                        {
                            "requirement_type": "volume",
                            "expected_value": "high"
                        }
                    ]
                },
                {
                    "exact_snippets": "radiologic impression",
                    "criterion": "radiologic impression",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "used to assess high volume disease"
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor markers",
                    "criterion": "tumor markers",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "used to assess high volume disease"
                        }
                    ]
                },
                {
                    "exact_snippets": "LDH",
                    "criterion": "LDH",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "used to assess high volume disease"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Availability of and patient acceptance of curative therapy.",
            "criterions": [
                {
                    "exact_snippets": "Availability of ... curative therapy",
                    "criterion": "curative therapy",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patient acceptance of curative therapy",
                    "criterion": "curative therapy",
                    "requirements": [
                        {
                            "requirement_type": "patient acceptance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of severe immune-mediated adverse reaction to immune checkpoint inhibitors.",
            "criterions": [
                {
                    "exact_snippets": "History of severe immune-mediated adverse reaction to immune checkpoint inhibitors.",
                    "criterion": "immune-mediated adverse reaction to immune checkpoint inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "history of severe reaction",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Known seropositivity for or active infection by the human immunodeficiency virus (HIV).",
            "criterions": [
                {
                    "exact_snippets": "Known seropositivity for ... the human immunodeficiency virus (HIV)",
                    "criterion": "HIV seropositivity",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active infection by the human immunodeficiency virus (HIV)",
                    "criterion": "active HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Any active Grade 3 or higher (per the NCI CTCAE, version 4.03) viral, bacterial, or fungal infection within 2 weeks of registration.",
            "criterions": [
                {
                    "exact_snippets": "Any active Grade 3 or higher (per the NCI CTCAE, version 4.03) viral, bacterial, or fungal infection within 2 weeks of registration.",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "NCI CTCAE v4.03"
                            }
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "viral",
                                "bacterial",
                                "fungal"
                            ]
                        },
                        {
                            "requirement_type": "time_since_onset",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known concurrent malignancy that is progressing or requires active treatment. EXCEPTIONS: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in-situ cervical cancer that has been treated with curative intent, prostate cancer confined to the prostate gland with Gleason score <6 or PSA <1, as well as any stage I cancer treated with curative intent or any prior cancer with a disease-free interval of ≥3 years.",
            "criterions": [
                {
                    "exact_snippets": "Known concurrent malignancy that is progressing or requires active treatment.",
                    "criterion": "concurrent malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "active treatment requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "EXCEPTIONS: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in-situ cervical cancer that has been treated with curative intent",
                    "criterion": "specific cancer types (basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in-situ cervical cancer)",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prostate cancer confined to the prostate gland with Gleason score <6 or PSA <1",
                    "criterion": "prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "confined to prostate gland",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "Gleason score",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "PSA",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any stage I cancer treated with curative intent",
                    "criterion": "stage I cancer treated with curative intent",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any prior cancer with a disease-free interval of ≥3 years",
                    "criterion": "prior cancer with disease-free interval",
                    "requirements": [
                        {
                            "requirement_type": "disease-free interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Nursing women",
            "criterions": [
                {
                    "exact_snippets": "Nursing women",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "nursing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other concurrent anti-cancer therapy (chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (used for a non-FDA approved indication and in the context of a research investigation)).",
            "criterions": [
                {
                    "exact_snippets": "Other concurrent anti-cancer therapy (chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (used for a non-FDA approved indication and in the context of a research investigation))",
                    "criterion": "concurrent anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "any ancillary therapy considered investigational (used for a non-FDA approved indication and in the context of a research investigation)",
                    "criterion": "ancillary therapy considered investigational",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or experimental therapies: ≤4 weeks (≤3 weeks with documented disease progression)",
            "criterions": [
                {
                    "exact_snippets": "Other monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or experimental therapies: ≤4 weeks (≤3 weeks with documented disease progression)",
                    "criterion": "prior therapy with other monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or experimental therapies",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "washout period with documented disease progression",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Immunodeficiency or immunosuppression, including systemic corticosteroids at >10mg/day prednisone or equivalent within 1 week prior to planned start of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Immunodeficiency",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "immunosuppression",
                    "criterion": "immunosuppression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "systemic corticosteroids at >10mg/day prednisone or equivalent within 1 week prior to planned start of study treatment",
                    "criterion": "systemic corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg/day prednisone or equivalent"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 1 week prior to planned start of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of non-infectious pneumonitis that required steroids, or current pneumonitis, or carcinomatous meningitis, or interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.",
            "criterions": [
                {
                    "exact_snippets": "History of non-infectious pneumonitis that required steroids",
                    "criterion": "non-infectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "required steroids"
                        }
                    ]
                },
                {
                    "exact_snippets": "current pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "current",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "interference with detection or management of suspected drug-related pulmonary toxicity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatment.",
            "criterions": [
                {
                    "exact_snippets": "Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatment.",
                    "criterion": "condom use during intercourse",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "during treatment"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "weeks after stopping treatment"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NSCLC patients only: prior chemotherapy or immunotherapy or a combination of chemotherapy and immunotherapy for stage IV NSCLC.",
            "criterions": [
                {
                    "exact_snippets": "NSCLC patients only",
                    "criterion": "non-small cell lung cancer (NSCLC) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior chemotherapy or immunotherapy or a combination of chemotherapy and immunotherapy for stage IV NSCLC",
                    "criterion": "prior systemic therapy for stage IV NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": [
                                "chemotherapy",
                                "immunotherapy",
                                "combination of chemotherapy and immunotherapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "a. For NSCLC cohort: i. Known EGFR mutations which are sensitive to available targeted inhibitor therapy (including, but not limited to, deletions in exon 19 and exon 21 [L858R] substitution mutations). All patients with non-squamous histology must have been tested for EGFR mutation status; use of an FDA-approved test is strongly encouraged. ii. Non-squamous histology and unknown or indeterminate EGFR status. b. Part D NSCLC cohort: Known ALK translocations which are sensitive to available targeted inhibitor therapy. If tested, use of an FDA-approved test is strongly encouraged. Patients with unknown or indeterminate ALK status may be enrolled.",
            "criterions": [
                {
                    "exact_snippets": "Known EGFR mutations which are sensitive to available targeted inhibitor therapy (including, but not limited to, deletions in exon 19 and exon 21 [L858R] substitution mutations)",
                    "criterion": "EGFR mutation",
                    "requirements": [
                        {
                            "requirement_type": "mutation type",
                            "expected_value": [
                                "deletions in exon 19",
                                "exon 21 [L858R] substitution mutations",
                                "other sensitive mutations"
                            ]
                        },
                        {
                            "requirement_type": "sensitivity to targeted inhibitor therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "All patients with non-squamous histology must have been tested for EGFR mutation status",
                    "criterion": "EGFR mutation testing",
                    "requirements": [
                        {
                            "requirement_type": "testing",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "histology",
                            "expected_value": "non-squamous"
                        }
                    ]
                },
                {
                    "exact_snippets": "use of an FDA-approved test is strongly encouraged",
                    "criterion": "EGFR mutation testing method",
                    "requirements": [
                        {
                            "requirement_type": "test type",
                            "expected_value": "FDA-approved"
                        }
                    ]
                },
                {
                    "exact_snippets": "Non-squamous histology and unknown or indeterminate EGFR status",
                    "criterion": "EGFR mutation status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "unknown",
                                "indeterminate"
                            ]
                        },
                        {
                            "requirement_type": "histology",
                            "expected_value": "non-squamous"
                        }
                    ]
                },
                {
                    "exact_snippets": "Known ALK translocations which are sensitive to available targeted inhibitor therapy",
                    "criterion": "ALK translocation",
                    "requirements": [
                        {
                            "requirement_type": "translocation type",
                            "expected_value": "sensitive to available targeted inhibitor therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "If tested, use of an FDA-approved test is strongly encouraged",
                    "criterion": "ALK translocation testing method",
                    "requirements": [
                        {
                            "requirement_type": "test type",
                            "expected_value": "FDA-approved"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with unknown or indeterminate ALK status may be enrolled",
                    "criterion": "ALK translocation status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "unknown",
                                "indeterminate"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Known history of active TB (Bacillus tuberculosis).",
            "criterions": [
                {
                    "exact_snippets": "Known history of active TB (Bacillus tuberculosis)",
                    "criterion": "active tuberculosis (TB) history",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prisoners or subjects who are involuntarily incarcerated.",
            "criterions": [
                {
                    "exact_snippets": "Prisoners",
                    "criterion": "prisoner status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects who are involuntarily incarcerated",
                    "criterion": "involuntary incarceration",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Portal vein thrombosis involving more than intrahepatic portal vein branches: thrombosis of the right or left portal vein branch or the bifurcation, partial or complete obstruction of the portal vein trunk.",
            "criterions": [
                {
                    "exact_snippets": "Portal vein thrombosis involving more than intrahepatic portal vein branches",
                    "criterion": "portal vein thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "extent",
                            "expected_value": "involving more than intrahepatic portal vein branches"
                        }
                    ]
                },
                {
                    "exact_snippets": "thrombosis of the right or left portal vein branch",
                    "criterion": "portal vein branch thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "thrombosis of ... the bifurcation",
                    "criterion": "portal vein bifurcation thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "partial or complete obstruction of the portal vein trunk",
                    "criterion": "portal vein trunk obstruction",
                    "requirements": [
                        {
                            "requirement_type": "obstruction",
                            "expected_value": [
                                "partial",
                                "complete"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant women or women of reproductive ability who are unwilling to use highly effective contraception",
            "criterions": [
                {
                    "exact_snippets": "Pregnant women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "women of reproductive ability ... unwilling to use highly effective contraception",
                    "criterion": "contraception use in women of reproductive ability",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use highly effective contraception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness",
            "criterions": [
                {
                    "exact_snippets": "compulsorily detained for treatment of either a psychiatric ... illness",
                    "criterion": "compulsory detention for psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "compulsorily detained for treatment of either a ... physical (e.g., infectious disease) illness",
                    "criterion": "compulsory detention for physical illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any serious health condition, which, in the opinion of the investigator, would place the patient at undue risk from the study, including uncontrolled hypertension and/or diabetes, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease requiring hospitalization within 3 months) or neurological disorder (e.g., seizure disorder active within 3 months)",
            "criterions": [
                {
                    "exact_snippets": "Any serious health condition, which, in the opinion of the investigator, would place the patient at undue risk from the study",
                    "criterion": "serious health condition",
                    "requirements": [
                        {
                            "requirement_type": "investigator opinion of risk",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled ... diabetes",
                    "criterion": "diabetes",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease requiring hospitalization within 3 months)",
                    "criterion": "pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "hospitalization for COPD within 3 months",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "neurological disorder (e.g., seizure disorder active within 3 months)",
                    "criterion": "neurological disorder",
                    "requirements": [
                        {
                            "requirement_type": "active within 3 months",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Neuroendocrine neoplasms described as \"well-differentiated\" or \"moderately differentiated\" on pathologic review, or reported as \"carcinoid\", i.e., not true poorly differentiated neuroendocrine carcinoma [Nagtegaal 2020].",
            "criterions": [
                {
                    "exact_snippets": "Neuroendocrine neoplasms described as \"well-differentiated\" or \"moderately differentiated\" on pathologic review",
                    "criterion": "neuroendocrine neoplasm differentiation",
                    "requirements": [
                        {
                            "requirement_type": "differentiation",
                            "expected_value": [
                                "well-differentiated",
                                "moderately differentiated"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "reported as \"carcinoid\"",
                    "criterion": "carcinoid tumor",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not true poorly differentiated neuroendocrine carcinoma",
                    "criterion": "poorly differentiated neuroendocrine carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "i. Previously received a CTLA-4 inhibitor in the first-line setting. ii. Relapsed/progressed during adjuvant immunotherapy with a PD-(L)1 inhibitor or relapse within 12 months after completion of adjuvant immunotherapy",
            "criterions": [
                {
                    "exact_snippets": "Previously received a CTLA-4 inhibitor in the first-line setting",
                    "criterion": "CTLA-4 inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment line",
                            "expected_value": "first-line"
                        }
                    ]
                },
                {
                    "exact_snippets": "Relapsed/progressed during adjuvant immunotherapy with a PD-(L)1 inhibitor",
                    "criterion": "relapse or progression during adjuvant immunotherapy with PD-(L)1 inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "progressed"
                            ]
                        },
                        {
                            "requirement_type": "treatment type",
                            "expected_value": "adjuvant immunotherapy with PD-(L)1 inhibitor"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "relapse within 12 months after completion of adjuvant immunotherapy",
                    "criterion": "relapse after adjuvant immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": "relapse"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months after completion of adjuvant immunotherapy"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "3. Acute hepatitis B or acute hepatitis C. Patients with chronic hepatitis B or hepatitis C may be enrolled provided their liver function is adequate as per section 3.17",
            "criterions": [
                {
                    "exact_snippets": "Acute hepatitis B",
                    "criterion": "hepatitis B",
                    "requirements": [
                        {
                            "requirement_type": "acuteness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Acute hepatitis C",
                    "criterion": "hepatitis C",
                    "requirements": [
                        {
                            "requirement_type": "acuteness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}